STOCK TITAN

Cbdmd Inc Financials

YCBD
Trailing 12 months to June 30, 2026
Revenue $20.9M +10.0% YoY
Net Income -$2.9M -90.8% YoY
EPS (Diluted) -$1.09 FY2025 annual
Free Cash Flow -$2.4M -95.0% YoY
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Jun 30, 2026 Reported Currency USD FYE September

Cbdmd Inc (YCBD) reported $20.9M in revenue over the twelve months to Jun 30, 2026, up 10.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI YCBD FY2025

The business is shrinking at the top line while cost reduction narrows losses without restoring cash self-funding.

From FY2023 to FY2025, revenue fell to $19.2M while operating margin improved from -93.1% to -11.3%, indicating that the recent earnings improvement is primarily an operating-cost adjustment rather than sales-led expansion. Yet FY2025 operating cash flow remained -$1.45M while financing cash flow contributed $1.45M, linking the narrower accounting loss to continued reliance on financing to offset cash use.

Gross margin stability near 62% across FY2023-FY2025, despite the contraction in revenue, suggests the core product economics were comparatively steady; the sharper change occurred below gross profit. The move in operating margin therefore points more to a reduced operating burden than to scale-driven leverage.

Shares outstanding rose from 492K in FY2024 to 8.9M in FY2025, so the balance-sheet improvement coincided with a materially changed equity base rather than arising solely from operations. Current ratio also moved from 0.7x to 2.1x, indicating that short-term balance-sheet pressure eased alongside the capital-structure change.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 38 / 100
Financial Health Score 38/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Cbdmd Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
48
Dilution
11
R&D Intensity
0

Not available for Cbdmd Inc, and counted as zero in the overall score.

Revenue Progress
33
Burn Trend
75
Balance Sheet
58
Altman Z-Score Distress
-21.52

Cbdmd Inc scores -21.52, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($5.6M) relative to total liabilities ($3.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
5/8

Cbdmd Inc passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing
N/A

Cbdmd Inc reported a net loss of $2.0M while operations used $1.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Cbdmd Inc reported an operating loss of $2.2M against $34K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$19.2M
YoY-1.5%
5Y CAGR-14.5%

Cbdmd Inc generated $19.2M in revenue in fiscal year 2025. This represents a decrease of 1.5% from the prior year.

EBITDA
-$1.0M
YoY+52.1%

Cbdmd Inc's EBITDA was -$1.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 52.1% from the prior year.

Net Income
-$2.0M
YoY+44.8%

Cbdmd Inc reported -$2.0M in net income in fiscal year 2025. This represents an increase of 44.8% from the prior year.

EPS (Diluted)
-$1.09

Cbdmd Inc earned -$1.09 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow
-$1.6M
YoY-201.5%

Cbdmd Inc recorded an outflow of $1.6M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 201.5% from the prior year.

Cash & Debt
$2.3M
YoY-7.8%
5Y CAGR-31.3%

Cbdmd Inc held $2.3M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding
9M

Cbdmd Inc had 9M shares outstanding in fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin
62.4%
YoY+0.8pp
5Y CAGR-0.6pp

Cbdmd Inc's gross margin was 62.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.8 percentage points from the prior year.

Operating Margin
-11.3%
YoY+5.8pp
5Y CAGR+30.7pp

Cbdmd Inc's operating margin was -11.3% in fiscal year 2025, reflecting core business profitability. This is up 5.8 percentage points from the prior year.

Net Margin
-10.6%
YoY+8.4pp
5Y CAGR-40.7pp

Cbdmd Inc's net profit margin was -10.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 8.4 percentage points from the prior year.

Return on Equity
-28.2%
YoY+160.2pp
5Y CAGR-44.2pp

Cbdmd Inc's ROE was -28.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 160.2 percentage points from the prior year.

Capital Allocation

Capital Expenditures
$184K
YoY-3.1%
5Y CAGR-32.6%

Cbdmd Inc invested $184K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 3.1% from the prior year.

R&D Spending

Not reported for fiscal year 2025.

Share Buybacks

Not reported for fiscal year 2025.

YCBD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

YCBD quarterly income statement
MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24
Revenue$5.6M-1.5%$5.6M+12.4%$5.0M+6.3%$4.7M+2.5%$4.6M-3.0%$4.7M-7.1%$5.1M+12.2%$4.6M
Cost of Revenue$2.5M+5.6%$2.4M+18.2%$2.0M+3.7%$1.9M+9.5%$1.8M-0.8%$1.8M+4.5%$1.7M-18.5%$2.1M
Gross Profit$3.0M-6.7%$3.3M+8.5%$3.0M+8.1%$2.8M-1.9%$2.8M-4.3%$3.0M-13.0%$3.4M+38.6%$2.5M
Operating Income-$1.1M-41.2%-$801K-179.7%-$286K+58.3%-$686K+24.2%-$905K-86.2%-$486K-463.1%-$86K+72.7%-$317K
Interest Expense$3K+16.7%$3K-11.1%$3K-46.0%$6K-37.9%$9K+23.2%$8K-33.0%$11K+456.0%$2K
Net Income-$1.1M-41.3%-$798K-181.8%-$283K+58.4%-$680K+24.0%-$895K-86.2%-$481K-3284.9%$15K+109.9%-$153K
EPS (Diluted)N/AN/AN/AN/AN/AN/AN/A$0.05

Not reported in any period shown, so not listed: R&D Expenses, SG&A Expenses, Income Tax.

YCBD Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

YCBD quarterly balance sheet
MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24
Total Assets$13.1M+7.3%$12.3M+4.0%$11.8M+13.1%$10.4M+5.3%$9.9M-9.5%$10.9M-5.2%$11.5M+9.1%$10.6M
Current Assets$7.7M-8.2%$8.4M+2.7%$8.2M+24.6%$6.6M+17.1%$5.6M-9.6%$6.2M-2.6%$6.4M-0.4%$6.4M
Cash & Equivalents$2.1M-19.7%$2.6M-22.1%$3.4M+49.8%$2.3M+113.4%$1.1M-40.0%$1.8M-10.4%$2.0M-19.7%$2.5M
Inventory$3.5M-5.1%$3.7M+16.2%$3.1M+6.7%$2.9M-7.3%$3.2M+10.2%$2.9M+16.6%$2.5M-2.0%$2.5M
Accounts Receivable$927K+12.9%$821K+10.2%$745K-5.3%$786K+5.4%$746K+7.4%$695K+10.1%$631K+1.5%$622K
Goodwill$190K0.0%$190KN/A$0N/AN/AN/AN/A
Total Liabilities$4.9M+66.2%$3.0M+7.0%$2.8M-13.1%$3.2M-15.6%$3.8M-63.2%$10.3M+5.2%$9.8M+13.3%$8.6M
Current Liabilities$3.1M+3.8%$3.0M+7.0%$2.8M-13.1%$3.2M-10.9%$3.6M-63.7%$9.9M+7.7%$9.2M+6.4%$8.6M
Total Equity$8.2M-11.6%$9.3M+3.1%$9.0M+24.7%$7.2M+18.3%$6.1M+817.8%$666K-62.6%$1.8M-9.3%$2.0M
Retained Earnings-$181.8M-0.7%-$180.6M-0.5%-$179.8M-0.2%-$179.4M-0.2%-$179.1M+3.0%-$184.5M-0.8%-$183.1M-0.5%-$182.1M

Not reported in any period shown, so not listed: Long-Term Debt.

YCBD Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

YCBD quarterly cash flow statement
MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24
Operating Cash Flow-$442K+38.8%-$723K+11.1%-$812K-237.5%-$241K+65.8%-$704K-271.7%-$189K+40.4%-$318K-290.0%$167K
Capital Expenditures$18K+214.3%$6K-96.5%$165K+5777.4%$3K+90.1%$1K-90.5%$16K-90.6%$164K+1543.9%$10K
Free Cash Flow-$460K+36.8%-$728K+25.5%-$977K-301.3%-$244K+65.5%-$706K-244.3%-$205K+57.5%-$482K-406.5%$157K
Investing Cash Flow-$18K-135.6%$51K+130.8%-$165K-5777.4%-$3K-90.1%-$1K+90.5%-$16K+90.6%-$164K-49.4%-$110K
Financing Cash Flow-$60K+23.4%-$78K-103.7%$2.1M+45.6%$1.4M$0$0$0-100.0%$1
Dividends PaidN/AN/AN/AN/AN/A$1.0M-0.6%$1.0MN/A

Not reported in any period shown, so not listed: Share Buybacks.

YCBD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

YCBD quarterly financial ratios
MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24
Gross Margin54.7%-3.1pp57.8%-2.1pp59.8%+1.0pp58.8%-2.6pp61.5%-0.9pp62.3%-4.2pp66.5%+12.7pp53.8%
Operating Margin-20.4%-6.2pp-14.2%-8.5pp-5.7%+8.8pp-14.5%+5.1pp-19.6%-9.4pp-10.2%-8.5pp-1.7%+5.3pp-7.0%
Net Margin-20.3%-6.2pp-14.1%-8.5pp-5.6%+8.8pp-14.4%+5.0pp-19.4%-9.3pp-10.1%-10.4pp0.3%+3.7pp-3.4%
Return on Equity-13.7%-5.1pp-8.6%-5.5pp-3.1%+6.3pp-9.4%+5.2pp-14.6%+57.6pp-72.2%-73.1pp0.9%+8.6pp-7.8%
Return on Assets-8.6%-2.1pp-6.5%-4.1pp-2.4%+4.1pp-6.5%+2.5pp-9.0%-4.7pp-4.4%-4.5pp0.1%+1.6pp-1.4%
Current Ratio2.50-0.3x2.82-0.1x2.94+0.9x2.05+0.5x1.56+0.9x0.63-0.1x0.690.0x0.74
Debt-to-Equity0.60+0.3x0.320.0x0.31-0.1x0.44-0.2x0.62-14.8x15.43+9.9x5.48+1.1x4.39
FCF Margin-8.3%+4.6pp-12.9%+6.6pp-19.5%-14.3pp-5.2%+10.2pp-15.3%-11.0pp-4.3%+5.1pp-9.4%-12.9pp3.5%

Similar Companies

Frequently Asked Questions

What is Cbdmd Inc's annual revenue?

Cbdmd Inc (YCBD) reported $19.2M in total revenue for fiscal year 2025. This represents a -1.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Cbdmd Inc's revenue growing?

Cbdmd Inc (YCBD) revenue declined by 1.5% year-over-year, from $19.5M to $19.2M in fiscal year 2025.

Is Cbdmd Inc profitable?

No, Cbdmd Inc (YCBD) reported a net income of -$2.0M in fiscal year 2025, with a net profit margin of -10.6%.

Cbdmd Inc (YCBD) reported diluted earnings per share of -$1.09 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Cbdmd Inc (YCBD) had EBITDA of -$1.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Cbdmd Inc (YCBD) had a gross margin of 62.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Cbdmd Inc (YCBD) had an operating margin of -11.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Cbdmd Inc (YCBD) had a net profit margin of -10.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Cbdmd Inc (YCBD) has a return on equity of -28.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Cbdmd Inc (YCBD) recorded an outflow of $1.6M in free cash flow during fiscal year 2025. This represents a -201.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Cbdmd Inc (YCBD) recorded an outflow of $1.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Cbdmd Inc (YCBD) had $10.4M in total assets as of fiscal year 2025, including both current and long-term assets.

Cbdmd Inc (YCBD) invested $184K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Cbdmd Inc (YCBD) had 9M shares outstanding as of fiscal year 2025.

Cbdmd Inc (YCBD) had a current ratio of 2.05 as of fiscal year 2025, which is generally considered healthy.

Cbdmd Inc (YCBD) had a debt-to-equity ratio of 0.44 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Cbdmd Inc (YCBD) had a return on assets of -19.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

At the end of fiscal year 2025, Cbdmd Inc (YCBD) held $3.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $1.5M over that year. Dividing the one by the other, the reported balance equals about 24 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Cbdmd Inc (YCBD) has an Altman Z-Score of -21.52, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Cbdmd Inc (YCBD) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Cbdmd Inc (YCBD) reported a net loss of $2.0M while operations used $1.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Cbdmd Inc (YCBD) reported an operating loss of $2.2M against $34K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Cbdmd Inc (YCBD) scores 38 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top